Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum

被引:19
作者
Ikeda, SI
Chisuwa, H
Kawasaki, S
Ozawa, J
Hoshii, Y
Yokota, T
Aoi, T
机构
[1] SHINSHU UNIV,SCH MED,DEPT SURG,MATSUMOTO,NAGANO 390,JAPAN
[2] SHINSHU UNIV HOSP,CENT CLIN LAB,MATSUMOTO,NAGANO 390,JAPAN
[3] YAMAGUCHI UNIV,SCH MED,DEPT PATHOL,UBE,YAMAGUCHI 744,JAPAN
[4] KOKURA MEM HOSP,DEPT PATHOL,KITAKYUSHU,FUKUOKA 802,JAPAN
[5] GAMAGOURI CITY HOSP,DEPT MED,AICHI 443,JAPAN
关键词
Castleman's disease; amyloid; serum amyloid A; interleukin; 6;
D O I
10.1136/jcp.50.11.965
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
A case is reported of a 21 year old woman who suffered from Castleman's disease and systemic reactive amyloidosis. The serum concentrations of serum amyloid A (SAA) and interleukin 6 (IL-6) were extremely high and amyloid protein was immunohistochemically identified as AA. After surgical excision of a large retroperitoneal lymph node with the pathological findings of plasma cell type of Castleman's disease, both serum SAA and IL-6 declined, showing a similar pattern of reduction curves. All clinical symptoms and laboratory abnormalities greatly improved. The biochemical feature of Castleman's disease is abnormal production of IL-6 and this cytokine continuously may stimulate the synthesis of an amyloid precursor, SAA, causing systemic reactive (AA) amyloidosis. This pathogenetic theory is strongly supported by the present study.
引用
收藏
页码:965 / 967
页数:3
相关论文
共 11 条
[1]  
BANKS RE, 1995, CLIN EXP IMMUNOL, V102, P217
[2]   ALLEVIATION OF SYSTEMIC MANIFESTATIONS OF CASTLEMANS DISEASE BY MONOCLONAL ANTI-INTERLEUKIN-6 ANTIBODY [J].
BECK, JT ;
HSU, SM ;
WIJDENES, J ;
BATAILLE, R ;
KLEIN, B ;
VESOLE, D ;
HAYDEN, K ;
JAGANNATH, S ;
BARLOGIE, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :602-605
[3]   RECOMBINANT HUMAN INTERLEUKIN-6 (IL-6/BSF-2/HSF) REGULATES THE SYNTHESIS OF ACUTE PHASE PROTEINS IN HUMAN HEPATOCYTES [J].
CASTELL, JV ;
GOMEZLECHON, MJ ;
DAVID, M ;
HIRANO, T ;
KISHIMOTO, T ;
HEINRICH, PC .
FEBS LETTERS, 1988, 232 (02) :347-350
[4]  
CHAN WC, 1984, CANCER, V53, P2135, DOI 10.1002/1097-0142(19840515)53:10<2135::AID-CNCR2820531024>3.0.CO
[5]  
2-N
[6]   A SYSTEMIC LYMPHOPROLIFERATIVE DISORDER WITH MORPHOLOGIC FEATURES OF CASTLEMANS DISEASE - CLINICAL FINDINGS AND CLINICOPATHOLOGIC CORRELATIONS IN 15 PATIENTS [J].
FRIZZERA, G ;
PETERSON, BA ;
BAYRD, ED ;
GOLDMAN, A .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (09) :1202-1216
[7]   SERUM AMYLOID-A (SAA) - BIOCHEMISTRY, GENETICS AND THE PATHOGENESIS OF AA AMYLOIDOSIS [J].
HUSBY, G ;
MARHAUG, G ;
DOWTON, B ;
SLETTEN, K ;
SIPE, JD .
AMYLOID-INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION, 1994, 1 (02) :119-137
[8]   CASTLEMAN DISEASE AND RENAL AMYLOIDOSIS [J].
KAZES, I ;
DERAY, G ;
JACOBS, C .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (05) :395-396
[9]   SECONDARY (AA) AMYLOIDOSIS ASSOCIATED WITH CASTLEMANS DISEASE - REPORT OF 2 CASES AND REVIEW OF THE LITERATURE [J].
ORDI, J ;
GRAU, JM ;
JUNQUE, A ;
NOMDEDEU, B ;
PALACIN, A ;
CARDESA, A .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1993, 100 (04) :394-397
[10]   REVERSAL OF NEPHROTIC SYNDROME DUE TO REACTIVE AMYLOIDOSIS (AA-TYPE) AFTER EXCISION OF LOCALIZED CASTLEMANS DISEASE [J].
PERFETTI, V ;
BELLOTTI, V ;
MAGGI, A ;
ARBUSTINI, E ;
DEBENEDETTI, F ;
PAULLI, M ;
MARINONE, MG ;
MERLINI, G .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 46 (03) :189-193